BIIB News 329.83 08/04/2014 04:44:47 Biogen Idec Inc (BIIB)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Idec Inc (BIIB) 329.83 $BIIB

Biotech Gets A Lift On Popular Drug, Strong Pipeline
at Investor's Business Daily - Fri Aug 01, 6:13PM CDT
The success of Biogen Idec's (BIIB) oral multiple sclerosis (MS) treatment Tecfidera has been well documented in recent quarters, but the company is far from a one-hit wonder. Its biggest seller is Avonex, an injectable MS treatment. Other Biogen...

Stock Market News for August 01, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 9:10AM CDT
Benchmarks suffered their biggest losses in months on Thursday, following a default by Argentina, and a spike in US labor costs

Favorable Court Ruling, Quarterly Performance Reviews, Acquisition Completion, and Contract Renewals - Research Reports on Mylan, Biogen, Medtronic, UnitedHealth and Covidien
PR Newswire - Fri Aug 01, 8:20AM CDT
Today, Analysts Review released its research reports regarding Mylan, Inc. (NASDAQ: MYL), Biogen Idec Inc. (NASDAQ: BIIB), Medtronic, Inc. (NYSE: MDT), UnitedHealth Group Inc. (NYSE: UNH) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5370-100free.

Stock Market News for July 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:10AM CDT
Benchmarks ended Wednesday’s choppy trading session little changed after the Federal Reserve offered a mixed view on the economy

Increased Earnings Estimates Seen for Biogen Idec (BIIB): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 7:57AM CDT
Biogen Idec could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions

Biotech Valuations Are Low Not Stretched. Here's Why.
at The Street - Thu Jul 31, 7:35AM CDT
If biotech companies can assuage concerns about long-term growth, multiples might expand.

Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 11:04AM CDT
Companies like Gilead and Biogen came out with impressive numbers thanks to the continued strong performance of new products.

Biogen Idec (BIIB) Highlighted As Momo Momentum Stock
at The Street - Wed Jul 30, 9:00AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate

Proteostasis Therapeutics Announces Achievement of Preclinical Milestone in Neurodegenerative Diseases Collaboration With Biogen Idec
Marketwire - Wed Jul 30, 4:30AM CDT
Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with orphan and neurodegenerative diseases, today announced that it has successfully completed a key preclinical milestone in the collaboration with Biogen Idec. Proteostasis has received a multimillion dollar milestone payment as a result of this achievement.

Biogen Idec Set to Possibly Pullback After Yesterday's Rally of 1.59%
Comtex SmarTrend(R) - Tue Jul 29, 3:56PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $335.70 to a high of $344.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $339.83 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Biogen Idec Rises 1.59% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jul 29, 3:56PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $335.70 to a high of $344.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $339.83 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Fairchild Semiconductor, E*Trade Financial, Gilead Sciences, Roche and Biogen Idec highlighted as Zacks Bull and Bear of the Day
PR Newswire - Tue Jul 29, 8:30AM CDT
Zacks Equity Research highlights Fairchild Semiconductor (Nasdaq:FCS -Free Report) as the Bull of the Day and E*Trade Financial (Nasdaq:ETFC -Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Gilead Sciences (Nasdaq:GILD -Free Report), Roche (OTC:RHHBY -Free Report) and Biogen Idec (Nasdaq:BIIB -Free Report).

Gilead's Oncology Drug Recommended for Approval in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:40PM CDT
Gilead's (GILD) Zydelig has been recommended for approval in the EU.

Jim Cramer Talks Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB) Stocks
at The Street - Mon Jul 28, 11:12AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions on Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB).

Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid

Chipotle, Facebook Rally On Upside Earnings Surprise
at Investor's Business Daily - Fri Jul 25, 5:36PM CDT
Several leading stocks enjoyed solid, earnings-powered breakouts last week. The IBD 50 outperformed the overall market with a 3.2% gain, thanks to some outsized performances by some big names. Chipotle Mexican Grill (CMG) gapped up and soared 12%...

Celgene Beats Q2 Earnings Estimates on Strong Revlimid Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 2:45PM CDT
Celgene (CELG) reported higher than expected earnings on strong revenues.

AbbVie Q2 Earnings Top on Humira Sales, Shire In Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 10:52AM CDT
AbbVie (ABBV) will provide additional details on the upcoming Shire acquisition this fall.

Exelixis (EXEL) Jumps: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 8:39AM CDT
Exelixis, Inc. (EXEL) was a big mover last session, as its shares rose over 11% on the day.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
CITGO Sign Return Caps Kenmore's Careful Rebuild Work

Updated Category News Views 88

Thirty feet upward and 120 feet eastward is not the sort of move that usually stops a city in its tracks, yet Boston’s CITGO Sign was never merely rooftop hardware. Its public relighting in Kenmore Square marks the final phase of the redevelopment at 660 Beacon Street, and the real accomplishment is less flashy than the lights: a beloved, federally landmarked object...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 83

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 121

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 73

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 108

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 61

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 90

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading

Top 5 Most Recently Viewed Articles

Nukkleus Stock Skyrockets 16% After Major Decision

Updated Category News Views 330

Nukkleus Inc. Stock Soars in After-Hours Trading Nukkleus Inc. (NASDAQ: NUKK) is making headlines as its shares have surged during after-hours trading following important developments within the company. This noteworthy stock movement reflects both investor sentiment and strategic changes that the company is undergoing. After-Hours Rally Sparks Investor Interest In recent...

Continue Reading
Tambourine One Revolutionizes Hotel Booking Experiences

Updated Category News Views 135

Introducing Tambourine One: A New Era in Hotel Booking Tambourine, the renowned leader in hotel marketing technology, has launched an innovative product known as Tambourine One. This all-in-one solution merges their advanced website technology with a booking engine, aimed at boosting direct bookings for hotels and resorts. By enhancing the booking process, Tambourine One...

Continue Reading
Midwest Great Dane: A New Era for Trudell Trailer Sales

Updated Category News Views 217

Midwest Great Dane Reveals Brand Transformation Midwest Great Dane, previously known as Trudell Trailer Sales, is making waves in the transportation and trucking industry with its recent name change. This transformation stems from a strategic acquisition by Cox Automotive, aimed at enhancing their representation of the Great Dane brand in the Midwest. The organization's...

Continue Reading
SoftServe Launches New Partner Unit to Boost AI Solutions

Updated Category News Views 334

SoftServe Unveils New Partner Business Unit for Enhanced AI Services SoftServe has officially launched its first dedicated Partner Business Unit (BU), marking a significant step forward in its strategic partnership with Microsoft. This initiative is designed to leverage SoftServe's extensive experience in technology and digital services, ensuring that organizations can...

Continue Reading
Portugal's Agri-Food Push in Canada: A Taste for Growth

Updated Category News Views 52

Eyeing Fresh Opportunities in Canada Here's a hot one for you—Portugal's agri-food sector is making a notable splash over in Canada. Yeah, you heard it right. Amidst the hustle and bustle of the SIAL Canada, which isn't just any minor shindig, "Taste & Feel Portugal 2.0" aims to put Portugal's top-tier grub on the map. It's about more than nibbling on cheese; it's a...

Continue Reading